Contineum Therapeutics (CTNM) Times Interest Earned (2023)

Contineum Therapeutics (CTNM) recorded quarterly Times Interest Earned of $335.66 in Q2 2023, up 703.74% quarter-over-quarter from -$55.6 in Q1 2023.

Contineum Therapeutics (CTNM) Times Interest Earned (2023) Analysis & Trends

Contineum Therapeutics' Times Interest Earned history runs 1 years deep, the most recent figure standing at $335.66 for Q2 2023.

  • In Q2 2023, Times Interest Earned changed N/A year-over-year to $335.66; the TTM figure through Mar 2024 stood at $0.61 (changed N/A YoY), while the FY2023 annual figure was $23.49, changed N/A from the prior year.
  • Times Interest Earned was $335.66 for Q2 2023 at Contineum Therapeutics, up from -$55.6 in the prior quarter.
  • In the past five years, Times Interest Earned ranged from a high of $335.66 in Q2 2023 to a low of -$55.6 in Q1 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Times Interest Earned (Qtr)
1 Alterity Therapeutics 762,369.55 Bn 762,369.51 Bn - -
2 Belite Bio 55,096.00 Bn 55,096.00 Bn - -
3 Quantum Biopharma 17,755.80 Bn 17,755.79 Bn - -
4 Legend Biotech 3,486.00 Bn 3,485.71 Bn 242.10 Mn 3.58
5 Akari Therapeutics 1,737.42 Bn 1,737.41 Bn - -258.33
6 Evaxion A 1,551.28 Bn 1,551.26 Bn - 11.50
7 Psyence Biomedical 227.32 Bn 227.31 Bn - 547.67
8 Vertex Pharmaceuticals 110.84 Bn 103.59 Bn 2.59 Bn -
9 Abivax 91.71 Bn 91.71 Bn - 11.79
10 Contineum Therapeutics 423.05 Mn 423.05 Mn - -

Historic Data

Download Data
DateValue
Jun 30, 2023 335.66
Mar 31, 2023 -55.60